Sort
51,593 grants matching “hepatitis”
Protective and fibrosis-independent functions of hepatic stellate cells
$499,972Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2024 · DK
Elucidating mechanisms of SIRT1 activation
$499,967David A. Sinclair · Harvard Medical School · R01 · FY2019 · DK
Trans Spinal Delivery of a Targeted Nanoformulation of Curcuminoids to Treat AD
$499,964Ramesh C Gupta · 3p Biotechnologies, Inc. · R41 · FY2024 · AG
SBIR Phase II: Bioinformatic Data Mining for AIDS Resistance Genes
$499,961Walter Messier · Evolutionary Genomics, Llc · · FY2005 · TIP
Testing Substrate-Flux Therapies for Glycosylation Disorders using Zebrafish
$499,941Hudson H Freeze · Sanford Burnham Prebys Medical Discovery Institute · RC1 · FY2010 · HD
Orally Active Nucleoside Phosphonates for Hepatitis C Virus
$499,920Robert Turner Schooley · University Of California, San Diego · R01 · FY2013 · AI
A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period
$499,879James G. Moe · Oligomerix, Inc · R44 · FY2025 · AG
The Role of Kisspeptin in Metabolism Regulation
$499,877Mehboob A Hussain · University Of California-Irvine · R01 · FY2024 · DK
Genetic Risk Stratification to Identify Individuals for Early Statin Therapy
$499,855Marc S Sabatine · Brigham And Women'S Hospital · RC1 · FY2009 · HL
Novel therapeutic approaches to treating chronic hepatitis B virus infection
$499,852Lishan Su · Univ Of North Carolina Chapel Hill · R01 · FY2013 · DK
Pathobiology of Hepatic Epithelia
$499,835Mayo Clinic · R01 · FY2005 · DK
The role of regulation and subcellular localization of GTP biosynthesis in melanoma invasion and metastasis
$499,833Mikhail Nikiforov · Duke University · R01 · FY2025 · CA
Novel determinants of fibrinogen pro-repair activity in acetaminophen-induced liver toxicity
$499,828James P Luyendyk · Michigan State University · R01 · FY2021 · DK
RAGE, DIAPH1 and IRF7 and Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Disease
$499,778Ann Marie Schmidt · New York University School Of Medicine · P01 · FY2024 · HL
An inbred mouse model for HCV infection, immunity andpathogenesis
$499,763Charles M. Rice · Rockefeller University · RC1 · FY2009 · DK
Jagged-Notch signaling in NASH/fibrosis
$499,751Utpal Pajvani · Columbia University Health Sciences · R01 · FY2021 · DK
Chronic Hepatitis Cohort StudyâII (CHeCSâII)
$499,736Stuart Gordon · Henry Ford Health System · U18 · FY2016 · PS
Clinical Prediction of Hepatotoxicity & Comparative Hepatic Safety of Medications
$499,729Vincent Lo Re · University Of Pennsylvania · R01 · FY2011 · HS
HIV Risk Behavior of Adult Minority Heterosexual Men in New York City
$499,723James M McMahon · University Of Rochester · R01 · FY2009 · HD
Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling
$499,701Shaodong Guo · Texas A&M Agrilife Research · R01 · FY2025 · DK
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES
$499,676Stanford University · R01 · FY2003 · HL
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES
$499,676Stanford University · R01 · FY2002 · HL
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES
$499,676Stanford University · R01 · FY2001 · HL
HIV SYNDROME X &PROTEASE INHIBITORS: HUMAN STUDIES
$499,676Stanford University · R01 · FY2004 · HL
Implementation science research on PrEP delivery and costing within MAT andNSP services for PWUD in Uganda
$499,636Renee A. Heffron · University Of Alabama At Birmingham · R01 · FY2023 · DA